Psychedelics in Finance
Mindmed's recent public offering on Nasdaq marks a significant moment for the psychedelic medicine sector, alongside Compass Pathways, which has raised substantial funds for research into psilocybin. Both companies aim to tackle treatment-resistant depression, presenting a promising alternative to traditional antidepressants. The conversation highlights the potential of psychedelics to address complex mental health challenges, moving beyond conventional approaches.In this clip
From this podcast
Equity
Tune in, SPAC on, drop LSD
Related Questions